Advent Capital Management
13F filer · CIK 0001097278Reported Aug 11, 2026
Net buyer this quarter
13F portfolio value$4.46BU.S. long equity reported on 13F
Positions3716 new · 17 closed
Net flow last quarter+$120MBuys minus sells
Top 10 positions weight7.4%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 11, 202637 positions | |||||
| $82.7M | 1.85% | Not reported | New | Q2 2026 | |
| $63.9M | 1.43% | Not reported | New | Q2 2026 | |
| $60.8M | 1.36% | Not reported | +8.4% | Q4 2025 | |
| $46.5M | 1.04% | Not reported | -20.6% | Q1 2025 | |
| $32.7M | 0.73% | Not reported | New | Q2 2026 | |
| $15.2M | 0.34% | Not reported | New | Q2 2026 | |
| $12.9M | 0.29% | 0.02% | Not reported | Q3 2018 | |
| $6.12M | 0.14% | Not reported | +0.4% | Q2 2024 | |
| $5.93M | 0.13% | Not reported | +3.1% | Q1 2025 | |
| $4.44M | 0.10% | Not reported | -85.9% | Q3 2025 | |
| $4.34M | 0.10% | 0.00% | -15.0% | Q3 2021 | |
| $4.26M | 0.10% | 0.00% | Not reported | Q2 2017 | |
| $3.47M | 0.08% | 0.00% | Not reported | Q1 2015 | |
| $3.41M | 0.08% | 0.00% | Not reported | Q4 2014 | |
| $3.32M | 0.07% | Not reported | New | Q2 2026 | |
| $3.14M | 0.07% | 0.00% | -16.7% | Q3 2017 | |
| $2.99M | 0.07% | Not reported | New | Q2 2026 | |
| $2.85M | 0.06% | 0.00% | Not reported | Q2 2015 | |
| $2.77M | 0.06% | Not reported | +1347.2% | Q1 2023 | |
| $2.62M | 0.06% | 0.00% | -31.3% | Q3 2021 | |
| $2.6M | 0.06% | 0.00% | Not reported | Q2 2014 | |
| $2.45M | 0.05% | 0.02% | -33.3% | Q1 2026 | |
| $2.43M | 0.05% | 0.01% | -32.0% | Q3 2018 | |
| $2.38M | 0.05% | 0.01% | -16.7% | Q4 2017 | |
| $2.34M | 0.05% | 0.00% | Not reported | Q3 2024 | |
| $2.2M | 0.05% | 0.00% | Not reported | Q3 2017 | |
| $2.08M | 0.05% | 0.00% | Not reported | Q3 2016 | |
| $881K | 0.02% | 0.01% | Not reported | Q4 2019 | |
| $824K | 0.02% | Not reported | New | Q2 2026 | |
| $381K | 0.01% | 0.05% | Not reported | Q1 2018 | |
| $254K | 0.01% | 0.00% | +66.7% | Q1 2026 | |
| $153K | 0.00% | 0.01% | +52.3% | Q4 2021 | |
| $19.7K | 0.00% | Not reported | Not reported | Q1 2025 | |
| $18.9K | 0.00% | 0.00% | Not reported | Q2 2018 | |
| $594 | 0.00% | Not reported | Not reported | Q4 2025 | |
| $339 | 0.00% | Not reported | Not reported | Q4 2025 | |
| $288 | 0.00% | Not reported | Not reported | Q4 2025 | |
| Q1 2026Reported May 7, 202638 positions | |||||
| $58.1M | 1.60% | Not reported | +22.3% | Q4 2025 | |
| $43.5M | 1.20% | Not reported | +43.6% | Q1 2025 | |
| $20.6M | 0.57% | Not reported | -18.0% | Q3 2025 | |
| $15.4M | 0.42% | Not reported | -50.6% | Q4 2025 | |
| $6.96M | 0.19% | Not reported | -7.5% | Q1 2025 | |
| $3.75M | 0.10% | Not reported | +94.5% | Q2 2024 | |
| $3.73M | 0.10% | 0.01% | +25.0% | Q2 2013 | |
| $3.68M | 0.10% | 0.01% | Not reported | Q1 2014 | |
| $3.66M | 0.10% | 0.00% | Not reported | Q1 2015 | |
| $3.58M | 0.10% | 0.00% | -23.1% | Q2 2017 | |
| $3.39M | 0.09% | 0.00% | Not reported | Q3 2025 | |
| $3.33M | 0.09% | 0.00% | Not reported | Q3 2021 | |
| $3.26M | 0.09% | 0.00% | Not reported | Q1 2015 | |
| $3.24M | 0.09% | 0.01% | +25.0% | Q3 2018 | |
| $3.12M | 0.09% | 0.00% | New | Q1 2026 | |
| $2.96M | 0.08% | 0.00% | Not reported | Q3 2017 | |
| $2.91M | 0.08% | 0.00% | Not reported | Q3 2018 | |
| $2.87M | 0.08% | Not reported | Not reported | Q1 2017 | |
| $2.84M | 0.08% | 0.00% | Not reported | Q2 2024 | |
| $2.84M | 0.08% | 0.00% | Not reported | Q2 2014 | |
| $2.72M | 0.07% | 0.00% | Not reported | Q3 2021 | |
| $2.5M | 0.07% | 0.05% | New | Q1 2026 | |
| $2.48M | 0.07% | 0.01% | Not reported | Q4 2017 | |
| $2.35M | 0.06% | 0.00% | New | Q1 2026 | |
| $2.16M | 0.06% | 0.05% | Not reported | Q4 2023 | |
| $2.03M | 0.06% | 0.01% | Not reported | Q3 2023 | |
| $1.93M | 0.05% | 0.04% | New | Q1 2026 | |
| $761K | 0.02% | 0.00% | Not reported | Q3 2015 | |
| $230K | 0.01% | 0.00% | New | Q1 2026 | |
| $156K | 0.00% | 0.00% | New | Q1 2026 | |
| $156K | 0.00% | Not reported | Not reported | Q1 2023 | |
| ETESPREsperion Therapeutics, Inc. | $137K | 0.00% | 0.02% | -44.4% | Q3 2025 |
| $78.6K | 0.00% | 0.01% | +109.5% | Q4 2021 | |
| $26.2K | 0.00% | 0.00% | Not reported | Q2 2018 | |
| $12.2K | 0.00% | Not reported | Not reported | Q1 2025 | |
| $725 | 0.00% | Not reported | Not reported | Q4 2025 | |
| $295 | 0.00% | Not reported | Not reported | Q4 2025 | |
| $282 | 0.00% | Not reported | Not reported | Q4 2025 | |
| Q4 2025Reported Feb 9, 202626 positions | |||||
| $45.6M | 0.92% | Not reported | New | Q4 2025 | |
| $31.7M | 0.64% | Not reported | New | Q4 2025 | |
| $31.5M | 0.63% | Not reported | -23.0% | Q3 2025 | |
| $31M | 0.62% | Not reported | -3.6% | Q1 2025 | |
| $8.36M | 0.17% | Not reported | +13.4% | Q1 2025 | |
| $4.14M | 0.08% | 0.00% | +30.0% | Q2 2017 | |
| $3.99M | 0.08% | 0.00% | Not reported | Q1 2025 | |
| $3.43M | 0.07% | 0.00% | Not reported | Q1 2015 | |
| $3.25M | 0.07% | 0.00% | Not reported | Q2 2013 | |
| $3.24M | 0.07% | 0.01% | +33.3% | Q3 2024 | |
| $3.05M | 0.06% | 0.01% | Not reported | Q3 2018 | |
| $2.92M | 0.06% | 0.00% | Not reported | Q3 2020 | |
| $2.86M | 0.06% | 0.00% | Not reported | Q2 2017 | |
| $2.77M | 0.06% | 0.00% | +60.0% | Q3 2018 | |
| $2.51M | 0.05% | 0.00% | +28.6% | Q3 2015 | |
| $1.71M | 0.03% | Not reported | -20.4% | Q2 2024 | |
| $705K | 0.01% | 0.00% | Not reported | Q1 2024 | |
| $701K | 0.01% | 0.04% | New | Q4 2025 | |
| APAPLSApellis Pharmaceuticals, Inc. | $452K | 0.01% | 0.01% | New | Q4 2025 |
| ETESPREsperion Therapeutics, Inc. | $333K | 0.01% | 0.04% | +12.5% | Q3 2025 |
| $29.2K | 0.00% | 0.00% | -68.7% | Q4 2021 | |
| $20.4K | 0.00% | 0.00% | Not reported | Q2 2018 | |
| $13.8K | 0.00% | Not reported | Not reported | Q1 2025 | |
| $1.08K | 0.00% | Not reported | New | Q4 2025 | |
| $624 | 0.00% | Not reported | New | Q4 2025 | |
| $479 | 0.00% | Not reported | New | Q4 2025 | |
| Q3 2025Reported Nov 13, 202523 positions | |||||
| $32.4M | 0.71% | Not reported | +24.4% | Q1 2025 | |
| $30.6M | 0.67% | Not reported | New | Q3 2025 | |
| $8.53M | 0.19% | Not reported | +134.2% | Q1 2025 | |
| $4.52M | 0.10% | 0.00% | +6.7% | Q3 2015 | |
| $4.29M | 0.09% | 0.01% | +20.0% | Q3 2024 | |
| $3.95M | 0.09% | 0.00% | +80.0% | Q3 2021 | |
| $3.74M | 0.08% | 0.00% | +233.3% | Q2 2017 | |
| $3.49M | 0.08% | 0.00% | New | Q3 2025 | |
| $3.38M | 0.07% | 0.00% | Not reported | Q1 2016 | |
| $3.33M | 0.07% | 0.00% | Not reported | Q2 2020 | |
| $2.84M | 0.06% | 0.01% | Not reported | Q3 2014 | |
| $2.82M | 0.06% | 0.00% | Not reported | Q4 2017 | |
| $2.53M | 0.06% | 0.00% | Not reported | Q2 2015 | |
| $2.43M | 0.05% | 0.03% | -26.3% | Q3 2013 | |
| $2.27M | 0.05% | 0.00% | Not reported | Q3 2015 | |
| $2.26M | 0.05% | 0.00% | Not reported | Q3 2024 | |
| $1.71M | 0.04% | Not reported | -19.2% | Q2 2024 | |
| $1.65M | 0.04% | 0.00% | -66.7% | Q3 2018 | |
| $766K | 0.02% | 0.18% | New | Q3 2025 | |
| $468K | 0.01% | 0.00% | New | Q3 2025 | |
| $300K | 0.01% | 0.01% | +219.1% | Q4 2021 | |
| ETESPREsperion Therapeutics, Inc. | $212K | 0.00% | 0.04% | New | Q3 2025 |
| $35.7K | 0.00% | Not reported | Not reported | Q1 2025 | |
Premium opens every quarter this fund has filed